{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:58:55Z","timestamp":1793271535234,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Commission Horizon 2020 Project EU-OPENSCREEN-DRIVE","award":["823893"],"award-info":[{"award-number":["823893"]}],"id":[{"id":"https:\/\/ror.org\/00k4n6c32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"European Commission Horizon 2020 Project EU-OPENSCREEN-DRIVE","award":["823893"],"award-info":[{"award-number":["823893"]}],"id":[{"id":"https:\/\/ror.org\/00k4n6c32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"European Commission Horizon 2020 Project EU-OPENSCREEN-DRIVE","award":["823893"],"award-info":[{"award-number":["823893"]}],"id":[{"id":"https:\/\/ror.org\/00k4n6c32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Education and Research","award":["13FH8I09IA"],"award-info":[{"award-number":["13FH8I09IA"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Education and Research","award":["13FH8I09IA"],"award-info":[{"award-number":["13FH8I09IA"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Education and Research","award":["13FH8I09IA"],"award-info":[{"award-number":["13FH8I09IA"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03446-1","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T13:10:25Z","timestamp":1748437825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity"],"prefix":"10.1038","volume":"15","author":[{"given":"Marcin Miko\u0142aj","family":"Grzybowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"U\u00e7al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Muchowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Rejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Kikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8686-774X","authenticated-orcid":false,"given":"Katarzyna Maria","family":"G\u0142uchowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Szostakowska-Rodzo\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Zago\u017cd\u017con","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bausbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Tkaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kulma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Ml\u0105cki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Konrad","family":"Jagielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"B\u0142aszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Hopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Zas\u0142ona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"3446_CR1","doi-asserted-by":"crossref","unstructured":"Can\u00e8, S., Geiger, R. & Bronte, V. The Roles of Arginases and Arginine in Immunity (Nature Reviews Immunology. Nature Research, 2024).","DOI":"10.1038\/s41577-024-01098-2"},{"issue":"6","key":"3446_CR2","doi-asserted-by":"publisher","first-page":"103579","DOI":"10.1016\/j.autrev.2024.103579","volume":"23","author":"C Chen","year":"2024","unstructured":"Chen, C., Han, P. & Qing, Y. Metabolic heterogeneity in tumor microenvironment \u2013 A novel landmark for immunotherapy. Autoimmun. Rev. 23 (6), 103579 (2024).","journal-title":"Autoimmun. Rev."},{"key":"3446_CR3","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. The significant role of amino acid metabolic reprogramming in cancer. Cell Commun Signal [Internet]. 2024 Jul 29 [cited 2025 Feb 24];22(1):380. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11285422\/","DOI":"10.1186\/s12964-024-01760-1"},{"key":"3446_CR4","doi-asserted-by":"crossref","unstructured":"Damiani, E. & Wallace, H. M. Polyamines and cancer. In: Methods in Molecular Biology. Humana Press Inc.; 469\u2013488. (2018).","DOI":"10.1007\/978-1-4939-7398-9_39"},{"key":"3446_CR5","doi-asserted-by":"publisher","unstructured":"Wu, J. Y. et al. Polyamine metabolism and anti-tumor immunity. Front Immunol [Internet]. Feb 18 [cited 2025 Feb 24];16:1529337. Available from: https:\/\/www.frontiersin.org\/articles\/ (2025). https:\/\/doi.org\/10.3389\/fimmu.2025.1529337\/full","DOI":"10.3389\/fimmu.2025.1529337\/full"},{"key":"3446_CR6","doi-asserted-by":"crossref","unstructured":"Avtandilyan, N., Javrushyan, H., Petrosyan, G. & Trchounian, A. The Involvement of Arginase and Nitric Oxide Synthase in Breast Cancer Development: Arginase and NO Synthase as Therapeutic Targets in Cancer. Biomed Res Int. ;2018. (2018).","DOI":"10.1155\/2018\/8696923"},{"key":"3446_CR7","doi-asserted-by":"crossref","unstructured":"Mintz, J. et al. Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. Vaccines (Basel) [Internet]. 2021 Feb 1 [cited 2025 Feb 23];9(2):94. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7912608\/","DOI":"10.3390\/vaccines9020094"},{"key":"3446_CR8","first-page":"776","volume":"1","author":"S Byers","year":"2020","unstructured":"Byers, S. et al. Proline metabolism in tumor growth and metastatic progression. Front. Oncol. | Www Frontiersin Org. [Internet]. 1, 776 (2020). Available from: www.frontiersin.org.","journal-title":"Front. Oncol. | Www Frontiersin Org. [Internet]"},{"key":"3446_CR9","doi-asserted-by":"crossref","unstructured":"Geng, P., Qin, W. & Xu, G. Proline Metabolism in Cancer. Vol. 53, Amino Acidsp. 1769\u20131777 (Springer, 2021).","DOI":"10.1007\/s00726-021-03060-1"},{"key":"3446_CR10","doi-asserted-by":"crossref","unstructured":"Phang, J. M., Liu, W., Hancock, C. N. & Fischer, J. W. Proline metabolism and cancer: emerging links to glutamine and collagen. Vol. 18, Current Opinion in Clinical Nutrition and Metabolic Care. Lippincott Williams and Wilkins; 71\u201377. (2015).","DOI":"10.1097\/MCO.0000000000000121"},{"key":"3446_CR11","doi-asserted-by":"crossref","unstructured":"Akinjiyan, F. A. et al. DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. Oncogene [Internet]. Jan 12 [cited 2025 Feb 24];43(3):189. (2023). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10786713\/","DOI":"10.1038\/s41388-023-02884-3"},{"key":"3446_CR12","doi-asserted-by":"crossref","unstructured":"Matos, A., Carvalho, M., Bicho, M. & Ribeiro, R. Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate cancer ProgressionVol. 13 (Nutrients. MDPI, 2021).","DOI":"10.3390\/nu13124503"},{"key":"3446_CR13","doi-asserted-by":"crossref","unstructured":"Novita Sari, I. et al. Metabolism and Function of Polyamines in cancer ProgressionVol. 519p. 91\u2013104 (Elsevier Ireland Ltd, 2021). Cancer Letters.","DOI":"10.1016\/j.canlet.2021.06.020"},{"key":"3446_CR14","doi-asserted-by":"crossref","unstructured":"Fatima, Z., Abonofal, A. & Stephen, B. Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors. J Immunother Precis Oncol [Internet]. 2023 May 1 [cited 2025 Feb 24];6(2):91. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10195018\/","DOI":"10.36401\/JIPO-22-27"},{"key":"3446_CR15","doi-asserted-by":"crossref","unstructured":"Li, H. et al. Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy. Front Immunol [Internet]. 2022 Dec 7 [cited 2025 Feb 24];13:1046755. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9768337\/","DOI":"10.3389\/fimmu.2022.1046755"},{"issue":"1","key":"3446_CR16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1186\/s12967-024-05652-3","volume":"22","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Engineered microparticles modulate arginine metabolism to repolarize tumor-associated macrophages for refractory colorectal cancer treatment. J. Transl Med. 22 (1), 908 (2024).","journal-title":"J. Transl Med."},{"key":"3446_CR17","doi-asserted-by":"publisher","unstructured":"Failla, M. et al. Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective. J Med Chem [Internet]. ; (2024). Available from: https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01429","DOI":"10.1021\/acs.jmedchem.4c01429"},{"key":"3446_CR18","unstructured":"Chen, J., Cui, L., Lu, S. & Xu, S. Amino acid metabolism in tumor biology and therapy. Cell Death & Disease 2024 15:1 [Internet]. 2024 Jan 13 [cited 2025 Feb 24];15(1):1\u201318. Available from: https:\/\/www.nature.com\/articles\/s41419-024-06435-w"},{"issue":"1","key":"3446_CR19","doi-asserted-by":"publisher","first-page":"115206","DOI":"10.1016\/j.celrep.2024.115206","volume":"44","author":"JE Ricci","year":"2025","unstructured":"Ricci, J. E. Tumor-induced metabolic immunosuppression: mechanisms and therapeutic targets. Cell. Rep. 44 (1), 115206 (2025).","journal-title":"Cell. Rep."},{"key":"3446_CR20","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Navas, R., Gajate, C. & Mollinedo, F. Neutrophils drive Endoplasmic reticulum stress-mediated apoptosis in cancer cells through arginase-1 release. Sci. Rep. ;11(1). (2021).","DOI":"10.1038\/s41598-021-91947-0"},{"key":"3446_CR21","doi-asserted-by":"crossref","unstructured":"Niu, F. et al. Arginase: an Emerging and Promising Therapeutic Target for cancer TreatmentVol. 149 (Elsevier Masson s.r.l., 2022). Biomedicine and Pharmacotherapy.","DOI":"10.1016\/j.biopha.2022.112840"},{"issue":"1\u20132","key":"3446_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cellimm.2005.01.004","volume":"232","author":"AH Zea","year":"2004","unstructured":"Zea, A. H. et al. l-Arginine modulates CD3\u03b6 expression and T cell function in activated human T lymphocytes. Cell. Immunol. 232 (1\u20132), 21\u201331 (2004).","journal-title":"Cell. Immunol."},{"key":"3446_CR23","doi-asserted-by":"publisher","unstructured":"Lu, J. et al. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Experimental Hematology & Oncology 2024 13:1 [Internet]. 2024 Apr 12 [cited 2025 Feb 24];13(1):1\u201324. Available from: https:\/\/ehoonline.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40164-024-00505-7","DOI":"10.1186\/s40164-024-00505-7"},{"key":"3446_CR24","unstructured":"Zaytouni, T. et al. Critical role for arginase 2 in obesity-associated pancreatic cancer. Nature Communications 2017 8:1 [Internet]. 2017 Aug 14 [cited 2025 Feb 24];8(1):1\u201312. Available from: https:\/\/www.nature.com\/articles\/s41467-017-00331-y"},{"key":"3446_CR25","doi-asserted-by":"crossref","unstructured":"Zhang, H. et al. Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc\u2013ODC1 nexus. Cancer Metab. ;12(1). (2024).","DOI":"10.1186\/s40170-024-00334-6"},{"key":"3446_CR26","doi-asserted-by":"crossref","unstructured":"Mart\u00ed i L\u00edndez, A. A. et al. Mitochondrial arginase-2 is a cell-autonomous regulator of CD8\u2009+\u2009T cell function and antitumor efficacy. JCI Insight ;4(24). (2019).","DOI":"10.1172\/jci.insight.132975"},{"key":"3446_CR27","doi-asserted-by":"crossref","unstructured":"Pudlo, M., Demougeot, C., Girard-Thernier, C. & Arginase Inhibitors A Rational Approach Over One Century. Med Res Rev [Internet]. 2017 May 1 [cited 2025 Feb 24];37(3):475\u2013513. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/med.21419","DOI":"10.1002\/med.21419"},{"key":"3446_CR28","doi-asserted-by":"crossref","unstructured":"Steggerda, S. M. et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J. Immunother Cancer ;5(1). (2017).","DOI":"10.1186\/s40425-017-0308-4"},{"key":"3446_CR29","doi-asserted-by":"crossref","unstructured":"Naing, A. et al. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. BMJ Oncol. ;3(1). (2024).","DOI":"10.1136\/bmjonc-2023-000249"},{"key":"3446_CR30","doi-asserted-by":"crossref","unstructured":"Grzybowski, M. M. et al. OATD-02 validates the benefits of Pharmacological Inhibition of arginase 1 and 2 in Cancer. Cancers (Basel) ;14(16). (2022).","DOI":"10.3390\/cancers14163967"},{"issue":"7","key":"3446_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/1535-7163.MCT-22-0721","volume":"22","author":"B Borek","year":"2023","unstructured":"Borek, B. et al. Arginase 1\/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy. Mol. Cancer Ther. 22 (7), 807\u2013817 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"3446_CR32","doi-asserted-by":"crossref","unstructured":"Dudek, M. A. et al. 717TiP An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and\/or metastatic solid tumors. Annals of Oncology [Internet]. 2023 Oct 1 [cited 2025 Mar 10];34:S495. Available from: https:\/\/www.annalsofoncology.org\/action\/showFullText?pii=S0923753423027400","DOI":"10.1016\/j.annonc.2023.09.1903"},{"key":"3446_CR33","doi-asserted-by":"crossref","unstructured":"Schulz, S., Becker, M., Groseclose, M. R., Schadt, S. & Hopf, C. Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development. Curr Opin Biotechnol [Internet]. Feb 1 [cited 2025 Mar 10];55:51\u20139. (2019). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30153614\/","DOI":"10.1016\/j.copbio.2018.08.003"},{"key":"3446_CR34","doi-asserted-by":"crossref","unstructured":"Spruill, M. L., Maletic-Savatic, M., Martin, H., Li, F. & Liu, X. Spatial analysis of drug absorption, distribution, metabolism, and toxicology using mass spectrometry imaging. Biochem Pharmacol [Internet]. 2022 Jul 1 [cited 2025 Mar 10];201. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35561842\/","DOI":"10.1016\/j.bcp.2022.115080"},{"key":"3446_CR35","doi-asserted-by":"crossref","unstructured":"Krause, I., Bockhardt, A., Neckermann, H., Henle, T. & Klostermeyer, H. Simultaneous determination of amino acids and biogenic amines by reversed-phase high-performance liquid chromatography of the Dabsyl derivatives. J. Chromatogr. A ;715(1). (1995).","DOI":"10.1016\/0021-9673(95)00578-B"},{"key":"3446_CR36","doi-asserted-by":"crossref","unstructured":"Ng, K. P. et al. The arginase inhibitor N\u03c9-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR\/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One ;13(10). (2018).","DOI":"10.1371\/journal.pone.0205254"},{"key":"3446_CR37","doi-asserted-by":"crossref","unstructured":"Sosnowska, A. et al. Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. Oncoimmunology ;10(1). (2021).","DOI":"10.1080\/2162402X.2021.1956143"},{"key":"3446_CR38","doi-asserted-by":"crossref","unstructured":"Borek, B., Gajda, T., Golebiowski, A. & Blaszczyk, R. Boronic acid-based Arginase Inhibitors in cancer ImmunotherapyVol. 28 (Elsevier Ltd, 2020). Bioorganic and Medicinal Chemistry.","DOI":"10.1016\/j.bmc.2020.115658"},{"issue":"6","key":"3446_CR39","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cmet.2018.04.009","volume":"27","author":"JD Ochocki","year":"2018","unstructured":"Ochocki, J. D. et al. Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor pyridoxal phosphate depletion and increased polyamine toxicity. Cell. Metab. 27 (6), 1263\u20131280e6 (2018).","journal-title":"Cell. Metab."},{"issue":"2","key":"3446_CR40","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1159\/000447790","volume":"39","author":"BA Setty","year":"2016","unstructured":"Setty, B. A. et al. Hypoxic proliferation of osteosarcoma cells depends on arginase II. Cell. Physiol. Biochem. 39 (2), 802\u2013813 (2016).","journal-title":"Cell. Physiol. Biochem."},{"key":"3446_CR41","doi-asserted-by":"crossref","unstructured":"Ino, Y. et al. Arginase II expressed in Cancer-Associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic Cancer. PLoS One ;8(2). (2013).","DOI":"10.1371\/journal.pone.0055146"},{"key":"3446_CR42","doi-asserted-by":"publisher","unstructured":"Emami Nejad, A. et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell International 2021 21:1 [Internet]. 2021 Jan 20 [cited 2025 Mar 10];21(1):1\u201326. Available from: https:\/\/cancerci.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12935-020-01719-5","DOI":"10.1186\/s12935-020-01719-5"},{"key":"3446_CR43","doi-asserted-by":"crossref","unstructured":"Andersen, M. K. et al. Spatial differentiation of metabolism in prostate cancer tissue by MALDI-TOF MSI. Cancer Metab. ;9(1). (2021).","DOI":"10.1186\/s40170-021-00242-z"},{"key":"3446_CR44","doi-asserted-by":"crossref","unstructured":"Abu Sammour, D. et al. Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors. Sci Rep [Internet]. 2019 Dec 1 [cited 2025 Mar 11];9(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31337874\/","DOI":"10.1038\/s41598-019-47089-5"},{"issue":"8","key":"3446_CR45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.neo.2016.07.002","volume":"18","author":"I Hinsenkamp","year":"2016","unstructured":"Hinsenkamp, I. et al. Inhibition of Rho-Associated kinase 1\/2 attenuates tumor growth in murine gastric Cancer. Neoplasia 18 (8), 500\u2013511 (2016).","journal-title":"Neoplasia"},{"key":"3446_CR46","doi-asserted-by":"publisher","unstructured":"Tufail, M., Jiang, C. H. & Li, N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Molecular Cancer 2024 23:1 [Internet]. 2024 Sep 18 [cited 2025 Mar 11];23(1):1\u201340. Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12943-024-02119-3","DOI":"10.1186\/s12943-024-02119-3"},{"key":"3446_CR47","doi-asserted-by":"crossref","unstructured":"Grzywa, T. M. et al. Potent but transient immunosuppression of T-cells is a general feature of CD71\u2009+\u2009erythroid cells. Commun. Biol. ;4(1). (2021).","DOI":"10.1038\/s42003-021-02914-4"},{"key":"3446_CR48","doi-asserted-by":"crossref","unstructured":"Pilanc, P. et al. A novel oral arginase 1\/2 inhibitor enhances the antitumor effect of PD-1 Inhibition in murine experimental gliomas by altering the immunosuppressive environment. Front. Oncol. ;11. (2021).","DOI":"10.3389\/fonc.2021.703465"},{"key":"3446_CR49","doi-asserted-by":"crossref","unstructured":"Chen, C. L., Hsu, S. C., Ann, D. K., Yen, Y. & Kung, H. J. Arginine Signaling and cancer MetabolismVol. 13 (Cancers. MDPI, 2021).","DOI":"10.3390\/cancers13143541"},{"key":"3446_CR50","doi-asserted-by":"crossref","unstructured":"Rodriguez, P. C. et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. Cancer Res [Internet]. Aug 15 [cited 2025 Feb 26];64(16):5839\u201349. (2004). Available from: \/cancerres\/article\/64\/16\/5839\/511544\/Arginase-I-Production-in-the-Tumor","DOI":"10.1158\/0008-5472.CAN-04-0465"},{"key":"3446_CR51","doi-asserted-by":"crossref","unstructured":"Czystowska-Kuzmicz, M. et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat. Commun. ;10(1). (2019).","DOI":"10.1038\/s41467-019-10979-3"},{"key":"3446_CR52","doi-asserted-by":"crossref","unstructured":"Casero, R. A., Murray Stewart, T. & Pegg, A. E. Polyamine Metabolism and Cancer: Treatments, Challenges and OpportunitiesVol. 18p. 681\u2013695 (Nature Publishing Group, 2018). Nature Reviews Cancer.","DOI":"10.1038\/s41568-018-0050-3"},{"key":"3446_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1073\/pnas.2305245120","volume":"120","author":"S Hibino","year":"2023","unstructured":"Hibino, S. et al. Tumor cell derived spermidine is an oncometabolite that suppresses TCR clustering for intratumoral CD8\u2009+\u2009T cell activation. Proc. Natl. Acad. Sci. U S A. 120, 24 (2023).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"3446_CR54","doi-asserted-by":"publisher","unstructured":"Kay, K. E. et al. Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8\u2009+\u2009T cell inhibition [Internet]. (2023). Available from: https:\/\/doi.org\/10.1101\/2023.11.14.567048","DOI":"10.1101\/2023.11.14.567048"},{"issue":"12","key":"3446_CR55","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/s42255-023-00919-3","volume":"5","author":"SJ Linder","year":"2023","unstructured":"Linder, S. J. et al. Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells. Nat. Metab. 5 (12), 2131\u20132147 (2023).","journal-title":"Nat. Metab."},{"key":"3446_CR56","doi-asserted-by":"crossref","unstructured":"D\u2019Aniello, C., Patriarca, E. J., Phang, J. M. & Minchiotti, G. Proline Metabolism in Tumor Growth and Metastatic ProgressionVol. 10 (Frontiers Media S.A., 2020). Frontiers in Oncology.","DOI":"10.3389\/fonc.2020.00776"},{"key":"3446_CR57","doi-asserted-by":"crossref","unstructured":"Wang, D. et al. Targeting the glutamine-arginine-proline Metabolism axis in cancerVol. 39 (Taylor and Francis Ltd., 2024). Journal of Enzyme Inhibition and Medicinal Chemistry.","DOI":"10.1080\/14756366.2024.2367129"},{"key":"3446_CR58","doi-asserted-by":"crossref","unstructured":"Phang, J. M. Proline Metabolism in Cell Regulation and cancer Biology: Recent Advances and HypothesesVol. 30p. 635\u2013649 (Mary Ann Liebert Inc., 2019). Antioxidants and Redox Signaling.","DOI":"10.1089\/ars.2017.7350"},{"key":"3446_CR59","doi-asserted-by":"crossref","unstructured":"Zea, A. H. et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res [Internet]. Apr 15 [cited 2025 Feb 26];65(8):3044\u20138. (2005). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15833831\/","DOI":"10.1158\/0008-5472.CAN-04-4505"},{"issue":"12","key":"3446_CR60","doi-asserted-by":"publisher","first-page":"9997","DOI":"10.1002\/jcp.29814","volume":"235","author":"Y Yu","year":"2020","unstructured":"Yu, Y. et al. Arginase-II promotes melanoma migration and adhesion through enhancing hydrogen peroxide production and STAT3 signaling. J. Cell. Physiol. 235 (12), 9997\u201310011 (2020).","journal-title":"J. Cell. Physiol."},{"key":"3446_CR61","doi-asserted-by":"crossref","unstructured":"Su, X. et al. Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment. J. Clin. Invest. ;131(20). (2021).","DOI":"10.1172\/JCI145296"},{"issue":"17","key":"3446_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21176282","volume":"21","author":"I Bednarz-Misa","year":"2020","unstructured":"Bednarz-Misa, I. et al. Esophageal squamous cell carcinoma is accompanied by local and systemic changes in L-arginine\/NO pathway. Int. J. Mol. Sci. 21 (17), 1\u201326 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"3446_CR63","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells. Cancer & Metabolism 2022 11:1 [Internet]. 2023 Jan 13 [cited 2025 Feb 24];11(1):1\u201314. Available from: https:\/\/cancerandmetabolism.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40170-022-00301-z","DOI":"10.1186\/s40170-022-00301-z"},{"issue":"5","key":"3446_CR64","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/ijc.23437","volume":"123","author":"R Rotondo","year":"2008","unstructured":"Rotondo, R. et al. Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. Int. J. Cancer. 123 (5), 1108\u20131116 (2008).","journal-title":"Int. J. Cancer"},{"issue":"2","key":"3446_CR65","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/j.cllc.2021.07.006","volume":"23","author":"S Umemura","year":"2022","unstructured":"Umemura, S. et al. Arginase pathway markers of Immune-Microenvironment in thymic epithelial tumors and small cell lung Cancer. Clin. Lung Cancer. 23 (2), e140\u2013e147 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"3446_CR66","doi-asserted-by":"crossref","unstructured":"Mussai, F. et al. Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. Int J Cancer [Internet]. Oct 15 [cited 2025 Feb 24];145(8):2201. (2019). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6767531\/","DOI":"10.1002\/ijc.32028"},{"key":"3446_CR67","doi-asserted-by":"publisher","unstructured":"Panina, S. B., Pei, J. & Kirienko, N. V. Mitochondrial metabolism as a target for acute myeloid leukemia treatment. [cited 2025 Feb 24]; Available from: https:\/\/doi.org\/10.1186\/s40170-021-00253-w","DOI":"10.1186\/s40170-021-00253-w"},{"key":"3446_CR68","doi-asserted-by":"crossref","unstructured":"Weis-Banke, S. E. et al. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells. J. Immunother Cancer ;10(10). (2022).","DOI":"10.1136\/jitc-2022-005326"},{"key":"3446_CR69","unstructured":"Mlynarski, S. N. et al. Discovery of (2R,4R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic acid (AZD0011), an actively transported prodrug of a potent arginase inhibitor to treat Cancer. J. Med. Chem. ; (2024)."},{"key":"3446_CR70","doi-asserted-by":"crossref","unstructured":"Doshi, A. S. et al. Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners. Mol Cancer Ther [Internet]. 2023 May 1 [cited 2025 Feb 26];22(5):630\u201345. Available from: \/mct\/article\/22\/5\/630\/726100\/Novel-Arginase-Inhibitor-AZD0011-Demonstrates.","DOI":"10.1158\/1535-7163.MCT-22-0431"},{"issue":"5","key":"3446_CR71","first-page":"1952","volume":"13","author":"PH Ye","year":"2023","unstructured":"Ye, P. H. et al. A novel combination therapy of arginine deiminase and an arginase inhibitor targeting arginine metabolism in the tumor and immune microenvironment. Am. J. Cancer Res. [Internet]. 13 (5), 1952\u20131969 (2023). Available from: www.ajcr.us\/.","journal-title":"Am. J. Cancer Res. [Internet]"},{"key":"3446_CR72","doi-asserted-by":"crossref","unstructured":"Zhu, S. et al. Combination Strategies To Maximize the Benefits of cancer ImmunotherapyVol. 14 (Journal of Hematology and Oncology. BioMed Central Ltd, 2021).","DOI":"10.1186\/s13045-021-01164-5"},{"key":"3446_CR73","doi-asserted-by":"crossref","unstructured":"Zaytouni, T. et al. Critical role for arginase 2 in obesity-Associated pancreatic cancer. Nat. Commun. ;8(1). (2017).","DOI":"10.1038\/s41467-017-00331-y"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03446-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T13:10:35Z","timestamp":1748437835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03446-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3446"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03446-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6305179\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Several authors (MMG, AM, AK, KG, MS-R, MK, AZ, PP, MM, AT, TR, RB, ZZ) are employees of Molecure SA, which holds proprietary rights to OATD-02. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures complied with the Public Health Service Policy on Humane Care and Use of Laboratory Animals and the Guidelines for the Welfare and Use of Animals in Cancer Research. Ethical approval for the study was granted by the 1\u2009st Local Ethics Committee for Animal Experiments in Warsaw, Poland (approval no. 891\/2019). All experiments were performed in accordance with relevant institutional and national guidelines and regulations. The study is reported in accordance with the ARRIVE guidelines (\n                      \n                      ). Procedures involving animals, including anesthesia and euthanasia, were conducted in accordance with veterinary best practice and followed the recommendations outlined in the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"18741"}}